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Chapter 1 cxplains lung canccr in tenns of cpidcrniology and
cument diagnostic management with i ts drawbacks. Lung cancer is not
oniy the rrost coulrlou canccr irr man but also one of the leading
callscs of cancer death in thc w'orld today. Accuratc staging of NSCLC
is essential in the decision rnaking of appropriate treatnrent since
sLlrgcry is thc trcatment witl-r the highest benef-rt. Besides asscsst-nent of
mediastinal ymph node rnetastases, pre-operative screcning focuses
also on thc dctection of distant rnetastases. Currcnt morphological
in-raging techniclues lack accurate detection of lr"rng cancer metastases.
Therefore, diagnostic stratcgies with niainly thesc tcchniqucs rcsult in
perfbrming Lrnnccessary surgr-ry in case of rnetastasizcd isease but
also in denial of potential ly curativc surgery. PET is uniquc as i t
erploits a different angle in diÍferentiating benign fiom rnalignant
t issue using mctabolic altcrations in discascd t issue. Exploring the
possibi l i t ies of PET in NSCLC is the basis of this thesis. The airns of
the thesis concludc haptcr l .
In chapter 2 thrce radiopharmaceuticals that havc been studicd
with PET fbr their fèasibi l i ty in imaging rnalignancics are brief ly
outl ined: FDG, TYR, and CHOL. Thc most widely applied PET
radiophannaceutical in oncology is the glucose analogue FDG.
NSCLC cells avidly incorporate FDG because they have an increased
rate of glycolysis and ovcrexprcssion of thc glucosc transportcr. Thc
rnetabolic pathway of FDG and the non.nal FDG body distribution is
discLrssed. Although t'DG PET may prove to be an accuratc non-
invasivc irnaging test Íbr dctecting malignancies, we shoLrld remember
tl iat FDG is not turnor spccif ic. Macrophagcs. granulation t issue and
necrosis may also show FDG accumulation. Thcrefbre, PET
rneasuring altcred substrate rcquiremcnts other than glucose is
interesting. TYR has proven to bc an appropriatc radiopharmaceutical
not only fbr thc dctection but also of the cluantiÍication of protein
syntlrcsis of rnalignart lcsions. More reccntly, CHOL has bcen
describcd as a PET radiophannaceutical fbr tumor detcction. As with
FDG, thc rnctabolic pathways o1' TYR and CHOL and their
distribution 'nvithin the bocly are discr-rssecl. Chapter 2 ends lvith a brief
cxplanation about quali tat ive and quantitat ive PET data analysis. In









































































quantification of the malignant metabolic rate is the main issue of
whole-body PET.
Given the moderate perfbrmance of conventional methods for
the staging of NSCLC, we have compared in chapter 3 thc ability of
FDG PET and conventional methods to stage NSCLC in 102 patients
with potentially resectable NSCLC. We have shown that FDG PET
improves the detection rate of both mediastinal lymph node
metastases and distant metastases. Of special interest is the high
negative predictive value of FDG PET for detecting both mediastinal
lymph node metastases and distant metastases. This can be used in
advantage of patients with NSCLC; with negative mediastinal and
distant FDG PET findings the surgeon may directly proceed to
thoracotomy. The advantage of whole-body PET is not only to
evaluate the primary tumor together with local metastases, but also
leads to the comect identification of patients with unsuspected
metastases. Although FDG PET, as compared to conventional
methods, improves the staging of NSCLC patients, it has its
limitations. Sensitivity and specificity of FDG PET are affected by
metabolic activity and volume of malignant lesions, tumor to
background contrast, PET image resolution and the presence or
absence of inflammation. Knowledge of these effects is necessary for
comect interpretation of FDG PET studies. Bearing this in mind, we
suggest hat implementing FDG PET as the initial investigation may
improve the efficacy of the diagnostic workup in patients with
NSCLC.
In the search for more specific PET radiopharmaceuticals, we
have investigated whether whole-body CHOL PET has advantages
over whole-body FDG PET in patients with thoracic cancer.
Although the short half-life of CHOL could limit the applicability of
whole-body scanning, in practice CHOL PET is feasible to obtain
images from crown to femur in patients with thoracic cancers. This is
appealing considering the ability of thoracic cancers to metastasize
locoregionally and hematogenously. CHOL PET gives clear images
with good contrast and can certainly be used to visualize malignant
tissue. However, as compared to FDG PET it is less accurate due to
lower accumulation of CHOL in malignant tissue. The inferiority is
most notable in the detection of lymph node metastases. CHOL PET
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shows superiority as compared to FDG PET in detecting brain
mctastascs, however, this is not surprising considering the
physiological glucose uptake by the brain. On the other hand, for
CHOL PET normal tracer accumulation hampers detection of
mctastases in liver and kidney since thcse oÍgans are major sites for
choline oxidation.
Most publications dealing with FDG PET in NSCLC arc based
on studies with attenuation comcction. Attenuation correction
improvcs anatomic orientation (c.g. discrimination of lung tissue fiorn
mcdiastinurn or liver) and attcnuation corrected irnages may be
evaluated quantitatively (e.g rcsearch purposes to provide a
qr"rantitative parametcr Íiorn thc study). However, such acquisitions
arc t imc consLrming and the vast majority of cl inical FDG PET studies
arc made for staging pluposes. i.e. lesion detcction rathcr than tracer
uptake quantification. Consequently, the relevance of perfonnir,g a
transmission scan fbr attcnuation corection can be qr-restioned if only
visual evaluation is needed for the staging of NSCLC paticnts. Tr.vo
independent observe rs blinded for clinical results str.rdied non-
attenuated and attcnuated corrected whole-body FDG PET images in
23 consecLrt ive patients with NSCLC. Comparing both types of scans,
attenuated corrcctcd scans show bctter delir-reation of internal organs.
BLrt in the assessment of hot spots no diffcrence was obserr,,ed
between both scanning rnethods. In othcr words: attcnuation
corrcction may not be neccssary for clinical staging ptrrposes in
paticnts with NSCLC. Considerir-rg the significant gron'tl.r in the
numbcr of cl inical FDG PET studies, scanner t irne is precious and
elimination of attcnuation correction sccms jLrsti f icd in cases of pure
FDG PET lcs ion detcct ion.
In chapter 4 wc discuss thc use of PET for post-treatment
evaluation of tumor rnetabolisr-r-r. Post-treatment analysis of tumor
metabolism by PET may be of intercst since anatomical imaging
modalities providc only a moderate correlation with survival in lung
cancer. We evaluated tnmor responsc measuren"lents with FDG PET
and CT in 75 lung canccr patients treated with chernotherapy. PET
and CT str"rdies were pcrformed within 2 weeks before start of
treatment and approximately 6 weeks afïer the cnd of the last cycle of








































































scored. In a lirnited number of patients quantitative analysis with PET
was performed of the primary tumor. It was shown that tracer uptake
of the primary tumor significantly decreases after treatment. In 640Á of
the patients PET and CT showed both the same response rates. Using
Kaplan-Meier and Cox regression analysis prognostic impact of tumor
response as measured with PET was significant when adjusted for CT,
while the impact of CT tumor measurements could not be
demonstrated.
Increased amino acid utilization for protein synthesis is also a
feature of malignancy. It is suggested that amino acids, as compared
to FDG, play a minor role in the metabolism of inflammatory cells. In
the post-treatment evaluation of tumor metabolisrn this may be of
importance since treatment rnay inducc inflamrnatory
hypermetabolism causing an overestimation of FDG r"rptake and
thereby misinterpretation of tumor response. Therefore, we evaluated
the potential role of TYR PET for the visualization and quantification
of protein metabolism of tumor tissue and normal lung tissue before
and after chernotherapy or radiotherapy. First, TYR appeared to be a
good tracer for the visualization and quantification of lung cancer.
Second, PSR as well as SUV, both measures of quantifying tracer
uptake, of tumor tissue decreased during the treatment course.
Persistent low uptake was observed in normal lung tissue, during and
after chemotherapy or radiotherapy. It should be noted that the PSR
reflects a dynamic measurement over tirne after injection of the tracer,
whereas the SUV reflects a static measuremcnt of uptake at a certain
chosen time point aÍter tracer injection. Therefore, PSR may be of
greater value for monitoring tumor responses to treatment. Since this
study was set up as a feasibility study, other studies arc needed to
asceftain whether TYR PET for the quantification of the PSR will
provide us with additional information with treatment implications in
patients with lung cancer.
In conclusion, we have shown that FDG PET as compared to
conventional staging methods improves the detection rate of both
mediastinal and distant metastases in patients with NSCLC. For
accnrate measurements of radiophannaceutical r"rptake attenLration
correction of the PET signal is obligatory, however, atteuuation
correction may be omitted for purposes of pure clinical staging in
t2 l
proven NSCLC patients. Comparing anatomical and rnetabolic tr.rmor
dimensions and their changes due to chcmotherapy, visually evaluated
FDG PET scans perfonn bctter than CT in response measurements.
Tumor response measurcd with FDG PET had also more prognostic
irnpact than CT measllrcment. In thc search fbr more specific PET
radiophannaccuticals, CHOL and TYR rvere investigated Íbr its
potential advantages ovcr FDG in patients with thoracic cancer.
CHOL PET can be used to visualize thoracic cancers and the detection
of brain rnctastases was superior. However, for the cletection of lyr-nph
node metastases CHOL PET was inlbrior comparcd with FDG PET.
TYR appcars to be a good tracer for visualizing lr-rng cancer and PSR
of tumor tissuc can be uscd to quantiÍy reduction in tl-re rnetabolic rate
of the tur-r-ror.
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